RBC Capital analyst Shagun Singh Chadha maintains $Abbott Laboratories (ABT.US)$ with a buy rating, and adjusts the target price from $125 to $130.
According to TipRanks data, the analyst has a success rate of 48.0% and a total average return of 0.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
The firm's industry checks indicate that Q3 underlying utilization trends were favorable, notwithstanding the usual summer seasonality which generally leads to a sequential decrease in elective procedures. Additionally, investor sentiment towards MedTech stocks is optimistic as the earnings season approaches, with expectations that investors will likely keep gravitating towards successful and catalyst-driven companies as the year concludes.
Abbott is described as a 'large-cap diversified healthcare play' with a dual nature. One side boasts an appealing medical technology segment that accounts for 45% of its global sales totaling $42B, which is growing annually at a rate of 11%-13%. On the other side, its non-medical technology operations are experiencing low- to mid-single-digit growth influenced by legal concerns surrounding its pediatric nutrition business and diminishing COVID-19 diagnostics sales. As these challenges in the non-MedTech sector diminish, Abbott is anticipated to face more favorable comparisons in fiscal 2026, leading to an acceleration in sales growth to low-double-digits and an improvement in EBIT margins.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇資本市場分析師Shagun Singh Chadha維持$雅培 (ABT.US)$買入評級，並將目標價從125美元上調至130美元。
根據TipRanks數據顯示，該分析師近一年總勝率為48.0%，總平均回報率為0.5%。
此外，綜合報道，$雅培 (ABT.US)$近期主要分析師觀點如下：
該公司的行業調查顯示，第三季度的基礎利用率趨勢良好，儘管通常的夏季季節性變化通常會導致選修程序的連續減少。此外，隨着業績期的臨近，投資者對醫療科技股票的情緒持樂觀態度，預計隨着業績期的臨近，投資者可能會繼續傾向於成功且具有催化劑驅動的公司。
雅培被描述爲具有雙重性質的 「大盤多元化醫療保健公司」。一方擁有吸引人的醫療技術細分市場，佔其全球銷售額的45％，總額爲420億美元，每年增長11％-13％。另一方面，受圍繞兒科營養業務的法律問題以及 COVID-19 診斷銷售減少的影響，其非醫療技術業務正在經歷低至中等個位數的增長。隨着非醫療技術領域的這些挑戰逐漸減少，預計雅培將在2026財年面臨更有利的比較，這將導致銷售增長加速至兩位數的低位數，息稅前利潤率的提高。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
